These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 7940560)
1. Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy. Allen DD; Orvig C; Yokel RA Toxicology; 1994 Sep; 92(1-3):193-202. PubMed ID: 7940560 [TBL] [Abstract][Full Text] [Related]
2. Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity. Yokel RA; Meurer KA; Hong CB; Dickey KM; Skinner TL; Fredenburg AM Drug Metab Dispos; 1997 Feb; 25(2):182-90. PubMed ID: 9029049 [TBL] [Abstract][Full Text] [Related]
3. The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine. Yokel RA; Meurer KA; Skinner TL; Fredenburg AM Drug Metab Dispos; 1996 Jan; 24(1):105-11. PubMed ID: 8825197 [TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Fredenburg AM; Sethi RK; Allen DD; Yokel RA Toxicology; 1996 Apr; 108(3):191-9. PubMed ID: 8658538 [TBL] [Abstract][Full Text] [Related]
5. Aluminum chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis. Yokel RA Biol Trace Elem Res; 1996; 53(1-3):193-203. PubMed ID: 8862748 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. Fredenburg AM; Wedlund PJ; Skinner TL; Damani LA; Hider RC; Yokel RA Drug Metab Dispos; 1993; 21(2):255-8. PubMed ID: 8097694 [TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats. Epemolu OR; Singh S; Hider RC; Damani LA Drug Metab Dispos; 1992; 20(5):736-41. PubMed ID: 1358580 [TBL] [Abstract][Full Text] [Related]
8. Combined chelation based on glycosyl-mono- and bis-hydroxypyridinones for aluminium mobilization: solution and biodistribution studies. Chaves S; Dron PI; Danalache FA; Sacoto D; Gano L; Santos MA J Inorg Biochem; 2009 Nov; 103(11):1521-9. PubMed ID: 19748126 [TBL] [Abstract][Full Text] [Related]
9. Chelation therapy in aluminum-loaded rats: influence of age. Gómez M; Esparza JL; Domingo JL; Singh PK; Jones MM Toxicology; 1999 Oct; 137(3):161-8. PubMed ID: 10522496 [TBL] [Abstract][Full Text] [Related]
10. Comparative aluminum mobilizing actions of deferoxamine and four 3-hydroxypyrid-4-ones in aluminum-loaded rats. Gómez M; Esparza JL; Domingo JL; Singh PK; Jones MM Toxicology; 1998 Sep; 130(2-3):175-81. PubMed ID: 9865484 [TBL] [Abstract][Full Text] [Related]
11. Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat. Choudhury R; Epemolu RO; Rai BL; Hider RC; Singh S Drug Metab Dispos; 1997 Mar; 25(3):332-9. PubMed ID: 9172951 [TBL] [Abstract][Full Text] [Related]
12. New tripodal hydroxypyridinone based chelating agents for Fe(III), Al(III) and Ga(III): Synthesis, physico-chemical properties and bioevaluation. Grazina R; Gano L; Sebestík J; Amelia Santos M J Inorg Biochem; 2009 Feb; 103(2):262-73. PubMed ID: 19062099 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and distribution of tris(maltolato)aluminum(III) into the central nervous system. Allen DD; Orvig C; Yokel RA Neurotoxicology; 1994; 15(2):371-8. PubMed ID: 7991226 [TBL] [Abstract][Full Text] [Related]
14. Adverse effects of aluminium-chelating compounds for clinical use. Domingo JL Adverse Drug React Toxicol Rev; 1996 Aug; 15(3):145-65. PubMed ID: 8931775 [No Abstract] [Full Text] [Related]
15. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site. Porter JB; Abeysinghe RD; Hoyes KP; Barra C; Huehns ER; Brooks PN; Blackwell MP; Araneta M; Brittenham G; Singh S Br J Haematol; 1993 Sep; 85(1):159-68. PubMed ID: 8251385 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum. Yokel RA; Datta AK; Jackson EG J Pharmacol Exp Ther; 1991 Apr; 257(1):100-6. PubMed ID: 2019981 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94. Chenoufi N; Hubert N; Loréal O; Morel I; Pasdeloup N; Cillard J; Brissot P; Lescoat G J Hepatol; 1995 Aug; 23(2):166-73. PubMed ID: 7499788 [TBL] [Abstract][Full Text] [Related]
18. Chelating effect of novel pyrimidines in a model of aluminum intoxication. Missel JR; Schetinger MR; Gioda CR; Bohrer DN; Pacholski IL; Zanatta N; Martins MA; Bonacorso H; Morsch VM J Inorg Biochem; 2005 Sep; 99(9):1853-7. PubMed ID: 16098596 [TBL] [Abstract][Full Text] [Related]
19. Kinetics of aluminum in rats I: Dose-dependent elimination from blood after intravenous administration. Pai SM; Melethil S J Pharm Sci; 1989 Mar; 78(3):200-2. PubMed ID: 2724077 [TBL] [Abstract][Full Text] [Related]
20. HPLC quantitation of a very hydrophilic 3-hydroxypyridin-4-one chelator using a simple separation procedure and the baseline file subtraction method. Skinner TL; Meurer KA; Yokel RA J Chromatogr Sci; 1996 Jan; 34(1):52-7. PubMed ID: 8586676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]